{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-295566","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.018473+00:00","generated_at":"2026-06-07T12:41:23.536486+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aadi Bioscience reports 26% ORR in TSC1 arm, 11% in TSC2 arm from PRECISION1 interim analysis","bullets":["TSC1 arm (n=22): 26% ORR (5 PRs, 4 confirmed), 42% clinical benefit rate, median 3 prior therapies.","TSC2 arm (n=18): 11% ORR (2 PRs, 1 confirmed), 28% clinical benefit rate, 50% had ≥5 prior lines.","No new safety signals; one grade 2 pneumonitis resolved; safety consistent with mTOR class.","80 patients now enrolled; two-thirds interim analysis expected 3Q 2024; trial completion by end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-295566","json":"https://secwatch.observer/filing/0001193125-23-295566.json","markdown":"https://secwatch.observer/filing/0001193125-23-295566.md","text":"https://secwatch.observer/filing/0001193125-23-295566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523295566/0001193125-23-295566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312523295566/d572047d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:41:23.536486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}